Acorah Software Products - Accounts Production 19.1.200 false true 31 October 2024 1 November 2023 false 1 November 2024 31 October 2025 31 October 2025 SC190038 R MacDonald Stronachs Secretaries Limited true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure SC190038 2024-10-31 SC190038 2025-10-31 SC190038 2024-11-01 2025-10-31 SC190038 frs-core:CurrentFinancialInstruments 2025-10-31 SC190038 frs-core:SharePremium 2025-10-31 SC190038 frs-core:ShareCapital 2025-10-31 SC190038 frs-core:RetainedEarningsAccumulatedLosses 2025-10-31 SC190038 frs-bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 SC190038 frs-bus:FilletedAccounts 2024-11-01 2025-10-31 SC190038 frs-bus:SmallEntities 2024-11-01 2025-10-31 SC190038 frs-bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 SC190038 frs-bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 SC190038 1 2024-11-01 2025-10-31 SC190038 frs-core:CostValuation 2024-10-31 SC190038 frs-core:CostValuation 2025-10-31 SC190038 frs-core:ProvisionsForImpairmentInvestments 2024-10-31 SC190038 frs-core:ProvisionsForImpairmentInvestments 2025-10-31 SC190038 frs-bus:Director1 2024-11-01 2025-10-31 SC190038 frs-bus:CompanySecretary1 2024-11-01 2025-10-31 SC190038 frs-countries:Scotland 2024-11-01 2025-10-31 SC190038 2023-10-31 SC190038 2024-10-31 SC190038 2023-11-01 2024-10-31 SC190038 frs-core:CurrentFinancialInstruments 2024-10-31 SC190038 frs-core:SharePremium 2024-10-31 SC190038 frs-core:ShareCapital 2024-10-31 SC190038 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31
Registered number: SC190038
Scottish Medicine Limited
Unaudited Financial Statements
For The Year Ended 31 October 2025
Infinity Advisors Ltd t/a Infinity Partnership
Scottish Medicine Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3

Page 1
Scottish Medicine Limited
Balance Sheet
As At 31 October 2025
Balance Sheet
Registered number: SC190038

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Investments | 4 |  | 1 |  | 1
|  |  | 1 |  | 1
CURRENT ASSETS
Debtors | 5 | 39,082 |  | 39,502 |
|  | 39,082 |  | 39,502 |
Creditors: Amounts Falling Due Within One Year | 6 | (6,352 ) |  | (6,352 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 32,730 |  | 33,150
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 32,731 |  | 33,151
NET ASSETS |  |  | 32,731 |  | 33,151
CAPITAL AND RESERVES
Called up share capital | 7 |  | 557,250 |  | 557,250
Share premium account |  |  | 4,587,750 |  | 4,587,750
Profit and Loss Account |  |  | (5,112,269 ) |  | (5,111,849 )
SHAREHOLDERS' FUNDS |  |  | 32,731 |  | 33,151

Page 1
Page 2
Scottish Medicine Limited
Balance Sheet (continued)
As At 31 October 2025
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

R MacDonald Director
17th April 2026

The notes on page 3 form part of these financial statements.
Page 2
Page 3
Scottish Medicine Limited
Notes to the Financial Statements
For The Year Ended 31 October 2025
Notes to the Financial Statements
1. General Information
Scottish Medicine Limited is a private company, limited by shares, incorporated in Scotland, registered number SC190038 . The registered office is 28 Albyn Place, Aberdeen, United Kingdom, AB10 1YL.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.
3. Average Number of Employees
Average number of employees, including directors, during the period was NIL (2024: NIL)
- -
4. Investments

| Subsidiaries
--- | ---
| £
Cost or Valuation
As at 1 November 2024 | 1
As at 31 October 2025 | 1
Provision
As at 1 November 2024 | -
As at 31 October 2025 | -
Net Book Value
As at 31 October 2025 | 1
As at 1 November 2024 | 1

5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Amounts owed by group undertakings | 39,082 |  | 39,502

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Amounts owed to group undertakings | 6,352 |  | 6,352

7. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 557,250 |  | 557,250

8. Ultimate Controlling Party
The controlling party is the copmpany shareholders.
Page 3